OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research report report published on Monday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.06.

OncoCyte Price Performance

OCX opened at $3.05 on Monday. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34. The company’s 50 day simple moving average is $3.08 and its 200 day simple moving average is $2.94.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.

Insider Activity at OncoCyte

In other news, CFO Andrea S. James purchased 33,670 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the acquisition, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, with a total value of $99,999.90. Following the acquisition, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.58% of the stock is owned by corporate insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.